SK Capital-backed SEQENS, a company that develops and produces active pharmaceutical ingredients, intermediates, and specialty ingredients, agreed to acquire CELLforCURE, a company that specializes in the development and custom production of cell & gene therapies, from Novartis, a Swiss multinational pharmaceutical corporation. Financial terms were not disclosed. With this contemplated acquisition, SEQENS has the ambition to bring all its industrial expertise and investment capacity with the aim of ensuring the company's long-term future, maintaining the recognized cell therapy skills of CELLforCURE's teams in France, completing its industrial facilities and pharmaceutical solutions offering, and strengthening its position as a leader in the development and production of essential medicines.